董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nicolas Fulpius | 男 | Non-Executive Director and Chairman of the Board | 44 | 未披露 | 未持股 | 2017-11-08 |
| Niels Riedemann | 男 | Executive Director and Chief Executive Officer | 45 | 未披露 | 未持股 | 2017-11-08 |
| Katrin Uschmann | 女 | Non-Executive Director | 53 | 未披露 | 未持股 | 2017-11-08 |
| Mark Kuebler | 男 | Non-Executive Director | 42 | 未披露 | 未持股 | 2017-11-08 |
| Lina Ma | 女 | Non-Executive Director | 40 | 未披露 | 未持股 | 2017-11-08 |
| Renfeng Guo | 男 | Executive Director and Chief Scientific Officer | 47 | 未披露 | 未持股 | 2017-11-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Niels Riedemann | 男 | Executive Director and Chief Executive Officer | 45 | 未披露 | 未持股 | 2017-11-08 |
| Renfeng Guo | 男 | Executive Director and Chief Scientific Officer | 47 | 未披露 | 未持股 | 2017-11-08 |
| Arnd Christ | 男 | Chief Financial Officer | 51 | 未披露 | 未持股 | 2017-11-08 |
| Othmar Zenker | 男 | Chief Medical Officer | 55 | 未披露 | 未持股 | 2017-11-08 |
| Maria Habel | 女 | Head of Preclinical Research and Development | 35 | 未披露 | 未持股 | 2017-11-08 |
| Katrin Reiher | 女 | Head of Quality Management | 35 | 未披露 | 未持股 | 2017-11-08 |
董事简历
中英对照 | 中文 | 英文- Nicolas Fulpius
-
Nicolas Fulpius，主席先生。Fulpius是我们的联合创始人之一，自2007年起担任董事和董事会主席。他曾一直担任Swisscom Schweiz AG的数字企业解决方案主管（2015年以来），也曾担任Veltigroup SA的首席执行官兼股东（2010年至2015年）。此前，他曾担任Affentrager Associates公司的合伙人兼股东（从2006年到2010年）、Ultreia Capital公司的投资董事兼股东（从2002年到2006年），以及Lombard Odier公司的投资经理（从1998年到2002年）。他曾一直担任IDROS S.A.的董事会主席（2016年以来），以及Anaroll Holding S.A.的董事会成员（2014年以来）、BRS Immobilier S.A.（2013年以来）、Affentrager Associates AG（2006年以来）、CIMA Corporate Investment Management Affentrager Holding AG（2006年以来）的董事会成员。他此前曾任职Swisscom Digital Technology S.A.、Akenes S.A.、Skwich Holding S.A.、Veltigroup S.A.、Lanexpert S.A.、Insentia S.A.、其信息技术服务S.A.、Epyx S.A.和Veltigroup Consulting S.A.的董事会。他持有Stanford University的管理科学和工程硕士学位，以及St.Gall University的瑞士相当于工商管理硕士学位。
Nicolas Fulpius, Chairman.Mr. Fulpius is one of our co-founders and has served as a director and chairman of our board since 2007. He has served as the Head of Digital Enterprise Solutions at Swisscom Schweiz AG since 2015 and was Chief Executive Officer and Shareholder of Veltigroup SA from 2010 to 2015. Prior to that role, he was a partner and shareholder in Affentrager Associates from 2006 to 2010 Investment Director and shareholder in Ultreia Capital from 2002 to 2006 and an Investment Manager at Lombard Odier from 1998 to 2002. He has served as chairman of the board of Idros S.A. since 2016 and as a member of the boards of Anaroll Holding S.A. since 2014 BRS Immobilier S.A. since 2013 Affentrager Associates AG since 2006 and CIMA Corporate Investment Management Affentrager Holding AG since 2006. He previously served on the boards of Swisscom Digital Technology S.A., Akenes S.A., Skwich Holding S.A., Veltigroup S.A., LANexpert S.A., insentia S.A., ITS Information Technologie Services S.A., epyx S.A. and Veltigroup Consulting S.A., among others. He holds an M.S. in Management Science and Engineering from Stanford University and the Swiss equivalent of an MBA from St. Gall University. - Nicolas Fulpius，主席先生。Fulpius是我们的联合创始人之一，自2007年起担任董事和董事会主席。他曾一直担任Swisscom Schweiz AG的数字企业解决方案主管（2015年以来），也曾担任Veltigroup SA的首席执行官兼股东（2010年至2015年）。此前，他曾担任Affentrager Associates公司的合伙人兼股东（从2006年到2010年）、Ultreia Capital公司的投资董事兼股东（从2002年到2006年），以及Lombard Odier公司的投资经理（从1998年到2002年）。他曾一直担任IDROS S.A.的董事会主席（2016年以来），以及Anaroll Holding S.A.的董事会成员（2014年以来）、BRS Immobilier S.A.（2013年以来）、Affentrager Associates AG（2006年以来）、CIMA Corporate Investment Management Affentrager Holding AG（2006年以来）的董事会成员。他此前曾任职Swisscom Digital Technology S.A.、Akenes S.A.、Skwich Holding S.A.、Veltigroup S.A.、Lanexpert S.A.、Insentia S.A.、其信息技术服务S.A.、Epyx S.A.和Veltigroup Consulting S.A.的董事会。他持有Stanford University的管理科学和工程硕士学位，以及St.Gall University的瑞士相当于工商管理硕士学位。
- Nicolas Fulpius, Chairman.Mr. Fulpius is one of our co-founders and has served as a director and chairman of our board since 2007. He has served as the Head of Digital Enterprise Solutions at Swisscom Schweiz AG since 2015 and was Chief Executive Officer and Shareholder of Veltigroup SA from 2010 to 2015. Prior to that role, he was a partner and shareholder in Affentrager Associates from 2006 to 2010 Investment Director and shareholder in Ultreia Capital from 2002 to 2006 and an Investment Manager at Lombard Odier from 1998 to 2002. He has served as chairman of the board of Idros S.A. since 2016 and as a member of the boards of Anaroll Holding S.A. since 2014 BRS Immobilier S.A. since 2013 Affentrager Associates AG since 2006 and CIMA Corporate Investment Management Affentrager Holding AG since 2006. He previously served on the boards of Swisscom Digital Technology S.A., Akenes S.A., Skwich Holding S.A., Veltigroup S.A., LANexpert S.A., insentia S.A., ITS Information Technologie Services S.A., epyx S.A. and Veltigroup Consulting S.A., among others. He holds an M.S. in Management Science and Engineering from Stanford University and the Swiss equivalent of an MBA from St. Gall University.
- Niels Riedemann
-
Niels Riedemann，首席执行官。Riedemann教授是我们的联合创始人之一，自2007年以来一直担任我们的首席执行官。他专门担任重症监护医生，并于2008年至2015年担任德国耶拿弗里德里希·席勒大学（Friedrich Schiller University）重症监护医学副主任。他花了几年时间在密歇根大学（University of Michigan）补体免疫学和炎症领域的基础科学工作，然后在汉诺威医学院（Hannover Medical School）完成普通外科医生的董事会认证，在那里他担任实验外科兼职教授。他曾一直担任the Center for Innovation Competition Sepomics（一个大型科学政府计划）的科学顾问委员会的成员（2015年以来），也曾任职the Center for Sepsis Control and Care（位于德国耶拿）的董事会（2014年至2015年）。Riedemann教授在德国弗赖堡Albert-Ludwig University和美国Stanford University接受医学培训，1998年毕业于Albert-Ludwig University。
Niels Riedemann, Chief Executive Officer.Professor Riedemann is one of our co-founders and has served as our Chief Executive Officer since 2007. He is specialized as an intensive care physician and was the Vice Director of Intensive Care Medicine at the Friedrich Schiller University in Jena, Germany from 2008 to 2015. He spent several years working in basic science at the University of Michigan in the field of complement immunology and inflammation before completing his board certification as General Surgeon at the Hannover Medical School where he holds an adjunct Professorship for Experimental Surgery. He has served as a member of the scientific advisory board of the Center for Innovation Competence Septomics, a large scientific governmental program, since 2015 and served on the board of directors of the Center for Sepsis Control and Care in Jena, Germany, from 2014 to 2015. Professor Riedemann received his medical training at the Albert-Ludwig University in Freiburg, Germany and Stanford University in the United States and graduated from Albert-Ludwig University in 1998. - Niels Riedemann，首席执行官。Riedemann教授是我们的联合创始人之一，自2007年以来一直担任我们的首席执行官。他专门担任重症监护医生，并于2008年至2015年担任德国耶拿弗里德里希·席勒大学（Friedrich Schiller University）重症监护医学副主任。他花了几年时间在密歇根大学（University of Michigan）补体免疫学和炎症领域的基础科学工作，然后在汉诺威医学院（Hannover Medical School）完成普通外科医生的董事会认证，在那里他担任实验外科兼职教授。他曾一直担任the Center for Innovation Competition Sepomics（一个大型科学政府计划）的科学顾问委员会的成员（2015年以来），也曾任职the Center for Sepsis Control and Care（位于德国耶拿）的董事会（2014年至2015年）。Riedemann教授在德国弗赖堡Albert-Ludwig University和美国Stanford University接受医学培训，1998年毕业于Albert-Ludwig University。
- Niels Riedemann, Chief Executive Officer.Professor Riedemann is one of our co-founders and has served as our Chief Executive Officer since 2007. He is specialized as an intensive care physician and was the Vice Director of Intensive Care Medicine at the Friedrich Schiller University in Jena, Germany from 2008 to 2015. He spent several years working in basic science at the University of Michigan in the field of complement immunology and inflammation before completing his board certification as General Surgeon at the Hannover Medical School where he holds an adjunct Professorship for Experimental Surgery. He has served as a member of the scientific advisory board of the Center for Innovation Competence Septomics, a large scientific governmental program, since 2015 and served on the board of directors of the Center for Sepsis Control and Care in Jena, Germany, from 2014 to 2015. Professor Riedemann received his medical training at the Albert-Ludwig University in Freiburg, Germany and Stanford University in the United States and graduated from Albert-Ludwig University in 1998.
- Katrin Uschmann
-
Katrin Uschmann.S.Uschmann于2007年加入我们的董事会，担任董事和副主席。她自1999年以来担任BeteiligungsManagement TH&252；Ringen GmbH的投资经理。在加入BeteiligungsManagement TH&252；Ringen GmbH之前，Uschmann女士在多家银行担任过各种职务，例如Bayerische Vereinsbank AG和TH&252；Ringer Aufbaubank的信贷分析师和公司关系经理，并在德国哥达高等专科学校（Fachhochschule）教授经济学。她曾一直任职Ezono AG的董事会（2007年以来），在那里她曾担任董事会副主席（2009年至2010年），也曾担任Preventicus GmbH公司的主席（2010年以来）。Uschmann女士此前曾于2011年至2017年担任AST Advanced Shockwave Technology Inc.的董事会成员。她持有Fachhochschule University of Applied Financial Sciences的熟练工人学位和工商管理硕士学位，以及GPM Deutsche Gesellschaft F&252；r ProjektManagement的项目管理学位。
Katrin Uschmann.Ms. Uschmann joined our board as a director and deputy chairwoman in 2007. She has served as an Investment Manager at beteiligungsmanagement thüringen gmbh since 1999. Prior to joining beteiligungsmanagement thüringen gmbh, Ms. Uschmann served in various roles at several banks, such as Credit Analyst and Corporate Relationship Manager at Bayerische Vereinsbank AG and at Thüringer Aufbaubank, and taught Economics at Fachhochschule in Gotha, Germany. She has served on the boards of eZono AG since 2007 where she was the board’s deputy chairwoman from 2009 to 2010 and has served as the chairwoman since 2010 and of Preventicus GmbH since 2014. Ms. Uschmann previously served on the board of AST Advanced Shockwave Technology Inc. from 2011 until 2017. She holds a skilled worker degree and an MBA from Fachhochschule University of Applied Financial Sciences, as well as a degree in project management from GPM Deutsche Gesellschaft für Projektmanagement. - Katrin Uschmann.S.Uschmann于2007年加入我们的董事会，担任董事和副主席。她自1999年以来担任BeteiligungsManagement TH&252；Ringen GmbH的投资经理。在加入BeteiligungsManagement TH&252；Ringen GmbH之前，Uschmann女士在多家银行担任过各种职务，例如Bayerische Vereinsbank AG和TH&252；Ringer Aufbaubank的信贷分析师和公司关系经理，并在德国哥达高等专科学校（Fachhochschule）教授经济学。她曾一直任职Ezono AG的董事会（2007年以来），在那里她曾担任董事会副主席（2009年至2010年），也曾担任Preventicus GmbH公司的主席（2010年以来）。Uschmann女士此前曾于2011年至2017年担任AST Advanced Shockwave Technology Inc.的董事会成员。她持有Fachhochschule University of Applied Financial Sciences的熟练工人学位和工商管理硕士学位，以及GPM Deutsche Gesellschaft F&252；r ProjektManagement的项目管理学位。
- Katrin Uschmann.Ms. Uschmann joined our board as a director and deputy chairwoman in 2007. She has served as an Investment Manager at beteiligungsmanagement thüringen gmbh since 1999. Prior to joining beteiligungsmanagement thüringen gmbh, Ms. Uschmann served in various roles at several banks, such as Credit Analyst and Corporate Relationship Manager at Bayerische Vereinsbank AG and at Thüringer Aufbaubank, and taught Economics at Fachhochschule in Gotha, Germany. She has served on the boards of eZono AG since 2007 where she was the board’s deputy chairwoman from 2009 to 2010 and has served as the chairwoman since 2010 and of Preventicus GmbH since 2014. Ms. Uschmann previously served on the board of AST Advanced Shockwave Technology Inc. from 2011 until 2017. She holds a skilled worker degree and an MBA from Fachhochschule University of Applied Financial Sciences, as well as a degree in project management from GPM Deutsche Gesellschaft für Projektmanagement.
- Mark Kuebler
-
Mark Kuebler。先生。Kuebler自2015年起担任董事会董事。Kuebler先生自2012年以来一直担任The Gig Ltd.的合伙人，该公司是一家风险投资咨询公司，在瑞士和马耳他设有办事处。他此前曾任职Sapphire Innovation AG（预测分析软件公司）、WWM AG和Jobydu AG（均位于瑞士）的董事会。Kuebler先生从2003年到2010年担任一家私募股权控股公司的常务董事兼公司秘书。2003年之前，他曾担任国际投资银行和精品店的多种职务。Kuebler先生拥有瑞士圣加仑大学（University of St.Gallen）的商业和经济学硕士学位，以及法学硕士学位。
Mark Kuebler.Mr. Kuebler has served as a director on our board since 2015. Mr. Kuebler has been a partner with the GIG Ltd., a venture capital advisory firm with offices in Switzerland and Malta, since 2012. He previously served on the boards of Sapphire Innovation AG, a predictive analytics software firm, as well as WWM AG and Jobydu AG, each based in Switzerland. Mr. Kuebler was a managing director and corporate secretary of a private equity holding company from 2003 to 2010. Before 2003 he held various roles in international investment banks and boutiques. Mr. Kuebler has a master’s degree in business and economics, as well as a master’s degree in law from the University of St. Gallen, in Switzerland. - Mark Kuebler。先生。Kuebler自2015年起担任董事会董事。Kuebler先生自2012年以来一直担任The Gig Ltd.的合伙人，该公司是一家风险投资咨询公司，在瑞士和马耳他设有办事处。他此前曾任职Sapphire Innovation AG（预测分析软件公司）、WWM AG和Jobydu AG（均位于瑞士）的董事会。Kuebler先生从2003年到2010年担任一家私募股权控股公司的常务董事兼公司秘书。2003年之前，他曾担任国际投资银行和精品店的多种职务。Kuebler先生拥有瑞士圣加仑大学（University of St.Gallen）的商业和经济学硕士学位，以及法学硕士学位。
- Mark Kuebler.Mr. Kuebler has served as a director on our board since 2015. Mr. Kuebler has been a partner with the GIG Ltd., a venture capital advisory firm with offices in Switzerland and Malta, since 2012. He previously served on the boards of Sapphire Innovation AG, a predictive analytics software firm, as well as WWM AG and Jobydu AG, each based in Switzerland. Mr. Kuebler was a managing director and corporate secretary of a private equity holding company from 2003 to 2010. Before 2003 he held various roles in international investment banks and boutiques. Mr. Kuebler has a master’s degree in business and economics, as well as a master’s degree in law from the University of St. Gallen, in Switzerland.
- Lina Ma
-
Lina Ma.S.Ma自2016年9月起担任董事会董事。马云自2012年6月起担任北京史泰信生物制药有限公司Vice President兼董事会秘书，自2015年9月起担任北京德丰瑞生物科技有限公司董事长，自2015年9月起担任加州史泰信生物制药有限公司公司秘书，自2013年以来，担任香港Staidson Hong Kong Investment Company Limited的首席执行官（2015年以来）。在此之前，她曾于2009年至2012年担任Joinn Laboratories（北京）舒泰神（北京）生物制药股份有限公司的总经理兼证券事务代表（2002年至2009年），并于2000年至2001年担任中国医学会远程医疗咨询中心的总经理兼证券事务代表。马女士拥有中国湖南医科大学学士学位和香港大学空间社区学院工商管理硕士学位。
Lina Ma.Ms. Ma has been a director on our board since September 2016. Ms. Ma has been the Vice President and Secretary of the board of Staidson Beijing BioPharmaceuticals Co., Ltd. since June 2012 the chairman of the board of Beijing Defengrei Biotechnology Co. Ltd since September 2015 the Company Secretary of Staidson BioPharma Inc., in California, since 2013 and the Chief Executive Officer of Staidson Hong Kong Investment Company Limited, in Hong Kong, since 2015. In previous roles, she has served as the General Manager and Securities Affair Representative of Staidson (Beijing) BioPharmaceuticals Co., Ltd. from 2009 to 2012 in JOINN Laboratories (Beijing) from 2002 to 2009 and in the China Medical Association Telemedicine Consultation Center from 2000 to 2001. Ms. Ma holds a bachelor’s degree from Hunan Medical University in China and an MBA from HKU SPACE Community College. - Lina Ma.S.Ma自2016年9月起担任董事会董事。马云自2012年6月起担任北京史泰信生物制药有限公司Vice President兼董事会秘书，自2015年9月起担任北京德丰瑞生物科技有限公司董事长，自2015年9月起担任加州史泰信生物制药有限公司公司秘书，自2013年以来，担任香港Staidson Hong Kong Investment Company Limited的首席执行官（2015年以来）。在此之前，她曾于2009年至2012年担任Joinn Laboratories（北京）舒泰神（北京）生物制药股份有限公司的总经理兼证券事务代表（2002年至2009年），并于2000年至2001年担任中国医学会远程医疗咨询中心的总经理兼证券事务代表。马女士拥有中国湖南医科大学学士学位和香港大学空间社区学院工商管理硕士学位。
- Lina Ma.Ms. Ma has been a director on our board since September 2016. Ms. Ma has been the Vice President and Secretary of the board of Staidson Beijing BioPharmaceuticals Co., Ltd. since June 2012 the chairman of the board of Beijing Defengrei Biotechnology Co. Ltd since September 2015 the Company Secretary of Staidson BioPharma Inc., in California, since 2013 and the Chief Executive Officer of Staidson Hong Kong Investment Company Limited, in Hong Kong, since 2015. In previous roles, she has served as the General Manager and Securities Affair Representative of Staidson (Beijing) BioPharmaceuticals Co., Ltd. from 2009 to 2012 in JOINN Laboratories (Beijing) from 2002 to 2009 and in the China Medical Association Telemedicine Consultation Center from 2000 to 2001. Ms. Ma holds a bachelor’s degree from Hunan Medical University in China and an MBA from HKU SPACE Community College.
- Renfeng Guo
-
Renfeng Guo，首席科学官。郭教授是我们的联合创始人之一，自2007年以来一直担任我们的首席科学官。加入我们之前，他曾担任密歇根大学（the University of Michigan）的教员（2001年以来），在那里他曾担任兼职副教授。郭教授在北京基础科学研究所担任名誉教授。郭教授在中国Norman Bethune医学院获得医学学位。
Renfeng Guo, Chief Scientific Officer.Professor Guo is one of our co-founders and has served as our Chief Scientific Officer since 2007. Prior to joining us, he served as a faculty member of the University of Michigan since 2001 where he holds a position as Adjunct Associate Professor. Professor Guo holds an Honorary Professorship at the Beijing Institute of Basic Sciences. Professor Guo received his medical degree from Norman Bethune Medical School in China. - Renfeng Guo，首席科学官。郭教授是我们的联合创始人之一，自2007年以来一直担任我们的首席科学官。加入我们之前，他曾担任密歇根大学（the University of Michigan）的教员（2001年以来），在那里他曾担任兼职副教授。郭教授在北京基础科学研究所担任名誉教授。郭教授在中国Norman Bethune医学院获得医学学位。
- Renfeng Guo, Chief Scientific Officer.Professor Guo is one of our co-founders and has served as our Chief Scientific Officer since 2007. Prior to joining us, he served as a faculty member of the University of Michigan since 2001 where he holds a position as Adjunct Associate Professor. Professor Guo holds an Honorary Professorship at the Beijing Institute of Basic Sciences. Professor Guo received his medical degree from Norman Bethune Medical School in China.
高管简历
中英对照 | 中文 | 英文- Niels Riedemann
Niels Riedemann，首席执行官。Riedemann教授是我们的联合创始人之一，自2007年以来一直担任我们的首席执行官。他专门担任重症监护医生，并于2008年至2015年担任德国耶拿弗里德里希·席勒大学（Friedrich Schiller University）重症监护医学副主任。他花了几年时间在密歇根大学（University of Michigan）补体免疫学和炎症领域的基础科学工作，然后在汉诺威医学院（Hannover Medical School）完成普通外科医生的董事会认证，在那里他担任实验外科兼职教授。他曾一直担任the Center for Innovation Competition Sepomics（一个大型科学政府计划）的科学顾问委员会的成员（2015年以来），也曾任职the Center for Sepsis Control and Care（位于德国耶拿）的董事会（2014年至2015年）。Riedemann教授在德国弗赖堡Albert-Ludwig University和美国Stanford University接受医学培训，1998年毕业于Albert-Ludwig University。
Niels Riedemann, Chief Executive Officer.Professor Riedemann is one of our co-founders and has served as our Chief Executive Officer since 2007. He is specialized as an intensive care physician and was the Vice Director of Intensive Care Medicine at the Friedrich Schiller University in Jena, Germany from 2008 to 2015. He spent several years working in basic science at the University of Michigan in the field of complement immunology and inflammation before completing his board certification as General Surgeon at the Hannover Medical School where he holds an adjunct Professorship for Experimental Surgery. He has served as a member of the scientific advisory board of the Center for Innovation Competence Septomics, a large scientific governmental program, since 2015 and served on the board of directors of the Center for Sepsis Control and Care in Jena, Germany, from 2014 to 2015. Professor Riedemann received his medical training at the Albert-Ludwig University in Freiburg, Germany and Stanford University in the United States and graduated from Albert-Ludwig University in 1998.- Niels Riedemann，首席执行官。Riedemann教授是我们的联合创始人之一，自2007年以来一直担任我们的首席执行官。他专门担任重症监护医生，并于2008年至2015年担任德国耶拿弗里德里希·席勒大学（Friedrich Schiller University）重症监护医学副主任。他花了几年时间在密歇根大学（University of Michigan）补体免疫学和炎症领域的基础科学工作，然后在汉诺威医学院（Hannover Medical School）完成普通外科医生的董事会认证，在那里他担任实验外科兼职教授。他曾一直担任the Center for Innovation Competition Sepomics（一个大型科学政府计划）的科学顾问委员会的成员（2015年以来），也曾任职the Center for Sepsis Control and Care（位于德国耶拿）的董事会（2014年至2015年）。Riedemann教授在德国弗赖堡Albert-Ludwig University和美国Stanford University接受医学培训，1998年毕业于Albert-Ludwig University。
- Niels Riedemann, Chief Executive Officer.Professor Riedemann is one of our co-founders and has served as our Chief Executive Officer since 2007. He is specialized as an intensive care physician and was the Vice Director of Intensive Care Medicine at the Friedrich Schiller University in Jena, Germany from 2008 to 2015. He spent several years working in basic science at the University of Michigan in the field of complement immunology and inflammation before completing his board certification as General Surgeon at the Hannover Medical School where he holds an adjunct Professorship for Experimental Surgery. He has served as a member of the scientific advisory board of the Center for Innovation Competence Septomics, a large scientific governmental program, since 2015 and served on the board of directors of the Center for Sepsis Control and Care in Jena, Germany, from 2014 to 2015. Professor Riedemann received his medical training at the Albert-Ludwig University in Freiburg, Germany and Stanford University in the United States and graduated from Albert-Ludwig University in 1998.
- Renfeng Guo
Renfeng Guo，首席科学官。郭教授是我们的联合创始人之一，自2007年以来一直担任我们的首席科学官。加入我们之前，他曾担任密歇根大学（the University of Michigan）的教员（2001年以来），在那里他曾担任兼职副教授。郭教授在北京基础科学研究所担任名誉教授。郭教授在中国Norman Bethune医学院获得医学学位。
Renfeng Guo, Chief Scientific Officer.Professor Guo is one of our co-founders and has served as our Chief Scientific Officer since 2007. Prior to joining us, he served as a faculty member of the University of Michigan since 2001 where he holds a position as Adjunct Associate Professor. Professor Guo holds an Honorary Professorship at the Beijing Institute of Basic Sciences. Professor Guo received his medical degree from Norman Bethune Medical School in China.- Renfeng Guo，首席科学官。郭教授是我们的联合创始人之一，自2007年以来一直担任我们的首席科学官。加入我们之前，他曾担任密歇根大学（the University of Michigan）的教员（2001年以来），在那里他曾担任兼职副教授。郭教授在北京基础科学研究所担任名誉教授。郭教授在中国Norman Bethune医学院获得医学学位。
- Renfeng Guo, Chief Scientific Officer.Professor Guo is one of our co-founders and has served as our Chief Scientific Officer since 2007. Prior to joining us, he served as a faculty member of the University of Michigan since 2001 where he holds a position as Adjunct Associate Professor. Professor Guo holds an Honorary Professorship at the Beijing Institute of Basic Sciences. Professor Guo received his medical degree from Norman Bethune Medical School in China.
- Arnd Christ
Arnd Christ，首席财务官先生。基督自2015年4月起担任我们的首席财务官。他也是CF Port GmbH的创始人兼董事总经理。在加入我们之前，他曾担任多家私人和公共生物技术公司的首席财务官。2012年至2014年，Christ先生担任Proteros Biostructure GmbH的首席财务官和执行董事会成员。在此之前，Christ先生于2010年至2012年担任Medigene AG的首席财务官兼执行董事会成员，2007年至2010年担任Novimmune S.A.的执行董事会成员，2002年至2007年担任益生菌制药AG的执行董事会成员，2001年至2002年担任Elegene AG的执行董事会成员。在加入生物技术行业之前，Christ先生从2000年到2001年担任德国Avery Dennison GmbH的财务总监，从1998年到1999年担任英国Herberts Industrial Coating Ltd.的财务总监。Christ先生拥有德国W&252；Rzburg大学的商业经济学学位。
Arnd Christ has served as Chief Financial Officer of Immatics OpCo since 2020. From 2015 to 2020 Mr. Christ served as Chief Financial Officer of InflaRx N.V., where he contributed to the successful listing of the company on Nasdaq. Prior to that, Mr. Christ served as Chief Financial Officer of Proteros Biostructure GmbH, as Chief Financial Officer of MediGene AG, as Chief Financial Officer of NovImmune SA, as Chief Financial Officer of Probiodrug AG, as Chief Financial Officer of EleGene AG, as Finance Director of Avery Dennison GmbH and as Finance Director of Herberts Industrial Coatings Ltd. Mr. Christ holds a diploma in business economics from the University of Würzburg, Germany.- Arnd Christ，首席财务官先生。基督自2015年4月起担任我们的首席财务官。他也是CF Port GmbH的创始人兼董事总经理。在加入我们之前，他曾担任多家私人和公共生物技术公司的首席财务官。2012年至2014年，Christ先生担任Proteros Biostructure GmbH的首席财务官和执行董事会成员。在此之前，Christ先生于2010年至2012年担任Medigene AG的首席财务官兼执行董事会成员，2007年至2010年担任Novimmune S.A.的执行董事会成员，2002年至2007年担任益生菌制药AG的执行董事会成员，2001年至2002年担任Elegene AG的执行董事会成员。在加入生物技术行业之前，Christ先生从2000年到2001年担任德国Avery Dennison GmbH的财务总监，从1998年到1999年担任英国Herberts Industrial Coating Ltd.的财务总监。Christ先生拥有德国W&252；Rzburg大学的商业经济学学位。
- Arnd Christ has served as Chief Financial Officer of Immatics OpCo since 2020. From 2015 to 2020 Mr. Christ served as Chief Financial Officer of InflaRx N.V., where he contributed to the successful listing of the company on Nasdaq. Prior to that, Mr. Christ served as Chief Financial Officer of Proteros Biostructure GmbH, as Chief Financial Officer of MediGene AG, as Chief Financial Officer of NovImmune SA, as Chief Financial Officer of Probiodrug AG, as Chief Financial Officer of EleGene AG, as Finance Director of Avery Dennison GmbH and as Finance Director of Herberts Industrial Coatings Ltd. Mr. Christ holds a diploma in business economics from the University of Würzburg, Germany.
- Othmar Zenker
Othmar Zenker，首席医疗官。Zenker自2013年起担任我们临床研究与开发计划的负责人，并于2017年成为我们的首席医疗官。在该职位上，他负责Inflarx的各种创新临床开发计划。在加入我们之前，Zenker博士在各种国际公司担任了20年的临床药物开发职务，包括Wyeth Pharmaceuticals和CSL Behring临床项目的领导职位。他此前曾担任CSL Behring公司的免疫学全球治疗领域主管。他从2000年到2012年在CSL Behring工作。Zenker先生于1990年在德国基尔医学院（Kiel Medical School）获得医学学位。
Othmar Zenker, Chief Medical Officer.Dr. Zenker has served as head of our clinical research and development programs since 2013 and became our Chief Medical Officer in 2017. In that role, he has responsibilities for various innovative clinical development programs at InflaRx. Prior to joining us, Dr. Zenker served in clinical drug development roles within various international companies for 20 years, including lead positions within clinical programs at Wyeth Pharmaceuticals and CSL Behring. He previously held a position as Global Therapeutic Area Head of Immunology at CSL Behring. He worked at CSL Behring from 2000 to 2012. Mr. Zenker received his medical degree from the Kiel Medical School in Germany in 1990.- Othmar Zenker，首席医疗官。Zenker自2013年起担任我们临床研究与开发计划的负责人，并于2017年成为我们的首席医疗官。在该职位上，他负责Inflarx的各种创新临床开发计划。在加入我们之前，Zenker博士在各种国际公司担任了20年的临床药物开发职务，包括Wyeth Pharmaceuticals和CSL Behring临床项目的领导职位。他此前曾担任CSL Behring公司的免疫学全球治疗领域主管。他从2000年到2012年在CSL Behring工作。Zenker先生于1990年在德国基尔医学院（Kiel Medical School）获得医学学位。
- Othmar Zenker, Chief Medical Officer.Dr. Zenker has served as head of our clinical research and development programs since 2013 and became our Chief Medical Officer in 2017. In that role, he has responsibilities for various innovative clinical development programs at InflaRx. Prior to joining us, Dr. Zenker served in clinical drug development roles within various international companies for 20 years, including lead positions within clinical programs at Wyeth Pharmaceuticals and CSL Behring. He previously held a position as Global Therapeutic Area Head of Immunology at CSL Behring. He worked at CSL Behring from 2000 to 2012. Mr. Zenker received his medical degree from the Kiel Medical School in Germany in 1990.
- Maria Habel
Maria Habel，研究与开发的负责人。Habel于2008年加入我们公司，担任实验室主管，并自公司成立以来一直为公司服务。自2013年以来，她一直负责所有临床前研究与开发计划，与补充系统以及我们的主要候选产品的特征相关的各种科学项目。此外，自2010年以来，Habel博士一直担任我们GMP制造活动中的质量控制主管。Habel博士于2008年在瑞士伯尔尼大学（University Bern）细胞与生物医学科学研究生院获得理学博士学位。
Maria Habel, Head of Research and Development.Dr. Habel joined our company in 2008 as Head of Laboratory and has served our company since our inception. Since 2013 she has taken on responsibilities for all pre-clinical research and development programs, various scientific projects related to the complement system as well as to the characterization of our lead product candidates. In addition, Dr. Habel has served as our Head of Quality Control within our GMP manufacturing activities since 2010. Dr. Habel received her Ph.D. in Science from the Graduate School for Cellular and Biomedical Science of the University Bern, Switzerland, in 2008.- Maria Habel，研究与开发的负责人。Habel于2008年加入我们公司，担任实验室主管，并自公司成立以来一直为公司服务。自2013年以来，她一直负责所有临床前研究与开发计划，与补充系统以及我们的主要候选产品的特征相关的各种科学项目。此外，自2010年以来，Habel博士一直担任我们GMP制造活动中的质量控制主管。Habel博士于2008年在瑞士伯尔尼大学（University Bern）细胞与生物医学科学研究生院获得理学博士学位。
- Maria Habel, Head of Research and Development.Dr. Habel joined our company in 2008 as Head of Laboratory and has served our company since our inception. Since 2013 she has taken on responsibilities for all pre-clinical research and development programs, various scientific projects related to the complement system as well as to the characterization of our lead product candidates. In addition, Dr. Habel has served as our Head of Quality Control within our GMP manufacturing activities since 2010. Dr. Habel received her Ph.D. in Science from the Graduate School for Cellular and Biomedical Science of the University Bern, Switzerland, in 2008.
- Katrin Reiher
Katrin Reiher，质量保证主管。Reiher于2008年加入我们公司，担任项目经理（2008年），并于2009年到2012年担任项目经理和质量经理。她于2013年开始担任我们的质量保证主管。Reiher女士于2006年获得德国德累斯顿理工大学（Technische Universit&228；T Dresden）的工商管理硕士学位。
Katrin Reiher, Head of Quality Assurance.Ms. Reiher joined our company in 2008 as a project manager in 2008 and served as a project manager and quality manager from 2009 to 2012. She began serving as our Head of Quality Assurance in 2013. Ms. Reiher received a Master’s degree in business administration from the Technische Universität Dresden in Germany in 2006.- Katrin Reiher，质量保证主管。Reiher于2008年加入我们公司，担任项目经理（2008年），并于2009年到2012年担任项目经理和质量经理。她于2013年开始担任我们的质量保证主管。Reiher女士于2006年获得德国德累斯顿理工大学（Technische Universit&228；T Dresden）的工商管理硕士学位。
- Katrin Reiher, Head of Quality Assurance.Ms. Reiher joined our company in 2008 as a project manager in 2008 and served as a project manager and quality manager from 2009 to 2012. She began serving as our Head of Quality Assurance in 2013. Ms. Reiher received a Master’s degree in business administration from the Technische Universität Dresden in Germany in 2006.